In this study, we evaluated the efficacy of the PAK1 inhibitor IPA‐3 as well as the BCAT1 inhibitors gabapentin and BCATc inhibitor 2 in CLL. This evidence concerns the gene PAK1 and B-cell chronic lymphocytic leukemia.